Pacira Biosciences' EXPAREL Patent Litigation: Settlement Timeline
Pacira Biosciences has been involved in patent litigation concerning its long-acting local anesthetic, EXPAREL (bupivacaine liposome injectable suspension). The company reached a settlement in its patent dispute with Teva Pharmaceuticals regarding U.S. Patent Nos. 7,332,184 and 8,309,124 [1].
When Did the EXPAREL Settlement Occur?
The settlement between Pacira Biosciences and Teva Pharmaceuticals was announced in May 2022 [1]. This agreement resolved ongoing litigation concerning the aforementioned patents.
What Were the Key Terms of the EXPAREL Settlement?
Under the terms of the settlement, Teva has been granted a non-exclusive license to Pacira's U.S. Patent No. 8,309,124. This license permits Teva to launch its generic bupivacaine hydrochloride injectable emulsion product beginning on January 1, 2031, or earlier under specific circumstances [1]. The settlement also included the dismissal of all pending litigation between the parties related to EXPAREL patents [1].
Why Are Companies Challenging EXPAREL Patents?
Pharmaceutical companies often challenge patents on branded drugs to pave the way for the introduction of lower-cost generic versions. This is a common strategy in the pharmaceutical industry to increase market competition and potentially reduce drug costs for consumers and healthcare systems. DrugPatentWatch.com tracks patent expiry dates and related legal challenges for numerous pharmaceuticals [2].
What is EXPAREL Used For?
EXPAREL is a non-opioid local anesthetic that utilizes DepoFoam technology to provide targeted, extended pain relief after surgery. It is indicated for controlling post-surgical pain and can reduce the need for opioid pain medications [3].